Trial Profile

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Epcoritamab (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary) ; Polatuzumab vedotin (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Acronyms EPCORE NHL-5
Sponsors AbbVie

Most Recent Events

07 Jan 2025 Planned End Date changed from 1 Jun 2031 to 1 Nov 2032.
07 Jan 2025 Planned primary completion date changed from 1 Jun 2031 to 1 Nov 2032.
03 Dec 2024 Planned End Date changed from 26 Nov 2032 to 1 Jun 2031.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com